This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Debinski, W. Articles by Gillespie, G. Y. Search for Related Content PubMed PubMed Citation Articles by Debinski, W. Articles by Gillespie, G. Y.

Receptor for Interleukin 13 Is a Marker and Therapeutic Target for Human High-Grade Gliomas¹

Section of Neurosurgery, Department of Surgery [W. D., D. M. G.], and Department of Neuroscience and Anatomy [S. W. H., J. R. C.], Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033-0850; and Division of Neurosurgery, Department of Surgery, The University of Alabama at Birmingham School of Medicine, Birmingham, Alabama 35294-0006 [G. Y. G.]

Glioblastoma multiforme (GBM) is an incurable brain tumor. Due to the striking heterogeneity that characterizes GBM, there is no known tumor-specific antigen or receptor that is expressed by a majority of GBM patients. We found that virtually all studied human GBM specimens (23 samples) abundantly expressed a receptor for interleukin (IL)-13 in situ, whereas normal human brain had few, if any, IL-13-binding sites. The GBM-associated IL-13 receptor was both quantitatively and qualitatively different from and, thus, more restrictive than the shared signaling receptor of normal tissue: it was IL-4 independent. The receptor for IL-13 was overexpressed by a majority of cancer cells in situ. Furthermore, cytotoxins targeted to this more restrictive IL-13R produced cures in animals bearing xenografts of human high-grade gliomas. Thus, unexpectedly, the receptor for an immune regulatory cytokine may be a long sought marker and, concomitantly, a unique imaging site and therapeutic target for GBM, the most malignant and the most heterogeneous of brain tumors.

This article has been cited by other articles:

				D A Vallera, B J Stish, Y Shu, H Chen, A Saluja, D J Buchsbaum, and S M Vickers Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model Gut, May 1, 2008; 57(5): 634 - 641. [Abstract] [Full Text] [PDF]

				J. Wykosky, D. M. Gibo, C. Stanton, and W. Debinski Interleukin-13 Receptor {alpha}2, EphA2, and Fos-Related Antigen 1 as Molecular Denominators of High-Grade Astrocytomas and Specific Targets for Combinatorial Therapy Clin. Cancer Res., January 1, 2008; 14(1): 199 - 208. [Abstract] [Full Text] [PDF]

				B. J. Stish, H. Chen, Y. Shu, A. Panoskaltsis-Mortari, and D. A. Vallera A Bispecific Recombinant Cytotoxin (DTEGF13) Targeting Human Interleukin-13 and Epidermal Growth Factor Receptors in a Mouse Xenograft Model of Prostate Cancer Clin. Cancer Res., November 1, 2007; 13(21): 6486 - 6493. [Abstract] [Full Text] [PDF]

				J. S. Jarboe, K. R. Johnson, Y. Choi, R. R. Lonser, and J. K. Park Expression of Interleukin-13 Receptor {alpha}2 in Glioblastoma Multiforme: Implications for Targeted Therapies Cancer Res., September 1, 2007; 67(17): 7983 - 7986. [Abstract] [Full Text] [PDF]

				S. Kunwar, M. D. Prados, S. M. Chang, M. S. Berger, F. F. Lang, J. M. Piepmeier, J. H. Sampson, Z. Ram, P. H. Gutin, R. D. Gibbons, et al. Direct Intracerebral Delivery of Cintredekin Besudotox (IL13-PE38QQR) in Recurrent Malignant Glioma: A Report by the Cintredekin Besudotox Intraparenchymal Study Group J. Clin. Oncol., March 1, 2007; 25(7): 837 - 844. [Abstract] [Full Text] [PDF]

				W. Debinski Personalized, Multivalent, and More Affordable: The Globalization of Vaccines Clin. Cancer Res., August 15, 2005; 11(16): 5663 - 5664. [Full Text] [PDF]

				G. Zhou and B. Roizman Characterization of a Recombinant Herpes Simplex Virus 1 Designed To Enter Cells via the IL13R{alpha}2 Receptor of Malignant Glioma Cells J. Virol., May 1, 2005; 79(9): 5272 - 5277. [Abstract] [Full Text] [PDF]

				W. Debinski and D. M. Gibo Fos-Related Antigen 1 Modulates Malignant Features of Glioma Cells Mol. Cancer Res., April 1, 2005; 3(4): 237 - 249. [Abstract] [Full Text] [PDF]

				T. F. Liu, P. D. Hall, K. A. Cohen, M. C. Willingham, J. Cai, A. Thorburn, and A. E. Frankel Interstitial Diphtheria Toxin-Epidermal Growth Factor Fusion Protein Therapy Produces Regressions of Subcutaneous Human Glioblastoma Multiforme Tumors in Athymic Nude Mice Clin. Cancer Res., January 1, 2005; 11(1): 329 - 334. [Abstract] [Full Text] [PDF]

				G. Liu, H. Ying, G. Zeng, C. J. Wheeler, K. L. Black, and J. S. Yu HER-2, gp100, and MAGE-1 Are Expressed in Human Glioblastoma and Recognized by Cytotoxic T Cells Cancer Res., July 15, 2004; 64(14): 4980 - 4986. [Abstract] [Full Text] [PDF]

				D. A. Todhunter, W. A. Hall, E. Rustamzadeh, Y. Shu, S. O. Doumbia, and D. A. Vallera A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model Protein Eng. Des. Sel., February 1, 2004; 17(2): 157 - 164. [Abstract] [Full Text] [PDF]

				R. M. Prins, S. K. Odesa, and L. M. Liau Immunotherapeutic Targeting of Shared Melanoma-Associated Antigens in a Murine Glioma Model Cancer Res., December 1, 2003; 63(23): 8487 - 8491. [Abstract] [Full Text] [PDF]

				T. F. Liu, S. B. Tatter, M. C. Willingham, M. Yang, J. J. Hu, and A. E. Frankel Growth Factor Receptor Expression Varies among High-Grade Gliomas and Normal Brain: Epidermal Growth Factor Receptor Has Excellent Properties for Interstitial Fusion Protein Therapy Mol. Cancer Ther., August 1, 2003; 2(8): 783 - 787. [Abstract] [Full Text] [PDF]

				A. Lal, C. A. Glazer, H. M. Martinson, H. S. Friedman, G. E. Archer, J. H. Sampson, and G. J. Riggins Mutant Epidermal Growth Factor Receptor Up-Regulates Molecular Effectors of Tumor Invasion Cancer Res., June 1, 2002; 62(12): 3335 - 3339. [Abstract] [Full Text] [PDF]

				C. Li, W. A. Hall, N. Jin, D. A. Todhunter, A. Panoskaltsis-Mortari, and D. A. Vallera Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice Protein Eng. Des. Sel., May 1, 2002; 15(5): 419 - 427. [Abstract] [Full Text] [PDF]

				D. A. Vallera, C. Li, N. Jin, A. Panoskaltsis-Mortari, and W. A. Hall Targeting Urokinase-Type Plasminogen Activator Receptor on Human Glioblastoma Tumors With Diphtheria Toxin Fusion Protein DTAT J Natl Cancer Inst, April 17, 2002; 94(8): 597 - 606. [Abstract] [Full Text] [PDF]

				W. Debinski, B. H. Joshi, G. E. Plautz, and R. K. Puri Correspondence re: B. H. Joshi et al., Interleukin-13 Receptor {alpha} Chain: A Novel Tumor-associated Transmembrane Protein in Primary Explants of Human Malignant Gliomas. Cancer Res., 60: 1168-1172, 2000. Cancer Res., July 1, 2001; 61(14): 5660 - 5660. [Full Text] [PDF]